Form 8-K - Current report:
SEC Accession No. 0001628280-25-022167
Filing Date
2025-05-05
Accepted
2025-05-05 16:07:56
Documents
14
Period of Report
2025-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cort-20250505.htm   iXBRL 8-K 24966
2 EX-99.1 exhibit991pressrelease0505.htm EX-99.1 66034
  Complete submission text file 0001628280-25-022167.txt   224607

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cort-20250505.xsd EX-101.SCH 1820
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cort-20250505_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cort-20250505_pre.xml EX-101.PRE 12544
16 EXTRACTED XBRL INSTANCE DOCUMENT cort-20250505_htm.xml XML 2727
Mailing Address 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065
Business Address 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065 650.688.8803
CORCEPT THERAPEUTICS INC (Filer) CIK: 0001088856 (see all company filings)

EIN.: 770487658 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50679 | Film No.: 25912970
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)